Special Issue "Antibody Conjugates"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 January 2012)
Dr. Surinder K Sharma
ADEPT & Translational Therapeutics, Cancer Institute, School of Life and Medical Sciences,University College London, London WC1E 6BT, UK
Interests: antibody; enzyme; drug; prodrug; antibody-enzyme conjugates; antibody-enzyme fusion proteins; immunogenicity
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
Article: Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease
Pharmaceuticals 2012, 5(1), 1-15; doi:10.3390/ph5010001
Received: 4 November 2011; in revised form: 6 December 2011 / Accepted: 14 December 2011 / Published: 22 December 2011| Download PDF Full-text (422 KB) | Download XML Full-text
Article: Poly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells
Pharmaceuticals 2012, 5(5), 405-416; doi:10.3390/ph5050405
Received: 8 February 2012; in revised form: 27 March 2012 / Accepted: 17 April 2012 / Published: 26 April 2012| Download PDF Full-text (774 KB) | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Human Enzymes for Antibody-Directed Enzyme Prodrug Therapy
Authors: Kai-Chuan Chen and Steve R Roffler
Affiliation: Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan; E-Mail: email@example.com
Abstract: Antibody-directed enzyme prodrug therapy (ADEPT) takes advantage of the high specificity of antibodies to target prodrug-activating enzymes to cancer cells for preferential activation of antineoplastic agents in the tumor microenvironment. Numerous targeting systems, prodrugs and enzymes have been investigated for ADEPT. Enzymes derived from microbial sources are usually highly specific and display good kinetic parameters for efficient prodrug activation. However, microbial enzymes tent to be highly immunogenic, which can limit clinical translation. To overcome this problem, various human enzymes have been developed for ADEPT. Here, we review the progress of using human enzymes for enzyme-prodrug therapy. Potential human enzymes which could be utilized for ADEPT are also discussed.
Last update: 28 November 2011